This study is part of the research undertaken in the EU funded project CLYMBOL ("Role of health-related CLaims and sYMBOLs in consumer behaviour"). The first phase of this project consisted of mapping the prevalence of symbolic and non-symbolic nutrition and health-related claims (NHC) on foods and non-alcoholic beverages in five European countries. Pre-packaged foods and drinks were sampled based on a standardized sampling protocol, using store lists or a store floor plan. Data collection took place across five countries, in three types of stores. A total of 2034 foods and drinks were sampled and packaging information was analyzed. At least one claim was identified for 26% (95% CI (24.0%-27.9%)) of all foods and drinks sampled. Six percent of these claims were symbolic. The majority of the claims were nutrition claims (64%), followed by health claims (29%) and health-related ingredient claims (6%). The most common health claims were nutrient and other function claims (47% of all claims), followed by disease risk reduction claims (5%). Eight percent of the health claims were children's development and health claims but these were only observed on less than 1% (0.4%-1.1%) of the foods. The category of foods for specific dietary use had the highest proportion of NHC (70% of foods carried a claim). The prevalence of symbolic and non-symbolic NHC varies across European countries and between different food categories. This study provides baseline data for policy makers and the food industry to monitor and evaluate the use of claims on food packaging.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808866 | PMC |
http://dx.doi.org/10.3390/nu8030137 | DOI Listing |
Int J Geriatr Psychiatry
January 2025
Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
Objectives: The diagnosis of early-onset Alzheimer's disease (EOAD) can cause emotional stress not only to the patients themselves but also to their spouses. This study aimed to evaluate the risk of psychiatric disorders in spouses of EOAD patients, using psychotropic drug initiation as a surrogate indicator.
Methods: A cohort study was conducted using a Japanese claims database, with spouses of EOAD patients (exposed spouses) matched with spouses of non-EOAD individuals (reference spouses) up to a 1:10 ratio.
BMC Health Serv Res
January 2025
Oral Health Initiative, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
Background: Despite assumptions that insurance coverage would boost oral healthcare utilization in Nigeria, there is insufficient evidence supporting this claim. This study investigates the associations between residential location, awareness of the oral health insurance scheme, history of dental service utilization, and acceptance of oral health insurance among individuals benefiting from the Ilera Eko Scheme; a scheme that integrates preventive and curative oral health care into the state health insurance scheme.
Methods: A cross-sectional survey was conducted from July to November 2023 recruiting from a database of 1520 enrollees aged of 18 and 72-years-old who had been on the scheme for at least three months.
Obes Surg
January 2025
H+ Yangji Hospital, Seoul, Republic of Korea.
Background: Although bariatric surgery is the most effective obesity treatment, few nationwide cohort studies have evaluated its safety. This study aimed to evaluate surgical trends after insurance coverage implementation and analyze the surgical outcomes of bariatric surgery.
Methods: A retrospective analysis of bariatric surgery in patients with obesity was conducted using data from Korean National Health Insurance System (NHIS) claims.
Tob Control
January 2025
Retired, University of California San Francisco, San Francisco, California, USA.
In 2024, Philip Morris International's (PMI) website stated they support 'independent' continuing medical education courses on harm reduction for medical and other healthcare professionals. These courses mirrored industry marketing and political strategies by presenting smokeless tobacco products and e-cigarettes as alternatives to smoking, sometimes without mentioning tobacco cessation. The enactment of the US Family Smoking and Tobacco Control Act gave the US Food and Drug Agency jurisdiction over tobacco products and included the industry's 'continuum of risk' frame, and emboldened tobacco companies to make harm reduction claims about these products, which they had previously avoided for fear of triggering restrictive regulation of cigarettes.
View Article and Find Full Text PDFBiomaterials
December 2024
Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Ophthalmology, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA, 23298, USA; Center for Pharmaceutical Engineering, Center for Drug Discovery, Department of Pediatrics, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, 23298, USA. Electronic address:
The opioid crisis has claimed approximately one million lives in the United States since 1999, underscoring a significant public health concern. This surge in opioid use disorder (OUD) fatalities necessitates improved therapeutic options. Current OUD therapies often require daily clinical visits, leading to poor patient compliance and high costs to the health systems.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!